ICER rates Astellas' potential menopausal symptom drug as promising at about $2K per year
The Institute for Clinical and Economic Review (ICER) on Thursday published a new evidence report for Astellas Pharma’s fezolinetant, recommending that the potential oral, non-hormonal drug designed to treat vasomotor symptoms associated with menopause should be priced between $2,000 and $2,500 per year for women who can’t or who choose not to take menopausal hormone therapy.
The cost-effectiveness nonprofit said the jury is still out on the effectiveness of the drug, which is due for an FDA decision by Feb. 22, 2023. Clinical evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for patients in the long term over no pharmacologic treatment, according to ICER.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
